Aurobindo Pharma Ltd (BOM:524804)
₹ 1267.4 -20.45 (-1.59%) Market Cap: 736.11 Bil Enterprise Value: 739.33 Bil PE Ratio: 21.08 PB Ratio: 2.49 GF Score: 91/100

Full Year 2020 Aurobindo Pharma Ltd Earnings Call Transcript

Jun 04, 2020 / 12:00PM GMT
Release Date Price: ₹759.15 (+1.13%)
Operator

Ladies and gentlemen, good day. And welcome to Aurobindo Pharma's Q4 FY '20 Earnings Conference Call. (Operator Instructions) Please note that this conference is being recorded.

I would now like to hand the conference over to Mr. Krishna Kiran, Investor Relations. Thank you, and over to you, sir.

Krishna Kiran
Aurobindo Pharma Limited - IR Officer

Yes. Thank you. Good morning, and a warm welcome to our fourth quarter and FY '20 earnings call. I am Krishna Kiran from the Aurobindo Pharma Investor Relations. We hope you have received Q4 FY '20 and FY '20 financials and the press release that we have sent out yesterday. These are also available on our website.

With me, we have our senior management team represented by Mr. P.V. Ram Prasad Reddy, Executive Chairman, Aurobindo Pharma USA; Mr. N. Govindarajan, Managing Director; Mr. Sanjeev Dani, COO and Head Formulations; Mr. Santhanam Subramanian, CFO; Mr. Swami Iyer, CFO Aurobindo Pharma USA.

We will begin the call with summary highlights from the management followed by an interactive

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot